Healthy Gains—Treating Obesity Is Good Business
November 20, 2026
As some employers roll back coverage for obesity management medications, the evidence points to the value of expanding access – not restricting it. Covering these treatments can reduce costly complications, strengthen employee retention and build a healthier, more productive workforce.
by the numbers: obesity care coverage pays off
Obesity management medications are critical interventions for reducing the risk of complications related to obesity – conditions that drive employer healthcare costs higher every year – and are an investment in employee retention and satisfaction.
- Employers and U.S. businesses pay $425.5 billion annually in care related to obesity and overweight.
- Adult large-employer plan members with an obesity or overweight diagnosis average $12,588 in annual health spending, versus $4,699 for those without a recorded diagnosis.
- A 2025 observational study found that GLP-1 medications can reduce the risk of 14 obesity-related cancers, while a workforce analysis conducted by Aon found that GLP-1 users experienced a nearly 40% reduction in hospitalizations caused by major adverse cardiovascular events.
- Employees who lose 5% of their body weight can reduce annual healthcare spending by an average of $670, and those who lose 25% can reduce that spending by $2,849 annually, according to Emory University researchers.
- 73% of employees say obesity management medication coverage is important when taking or staying at a job.
When employers cover the full continuum of obesity care, they also help level a playing field stacked against women living with obesity, who are too often judged by their body size rather than their capabilities.
- Obesity reduces women’s earnings by 9% and lowers the odds of employment by 20%, compared with women at a healthy weight.
- A working paper by economist Rebecca Diamond on the obesity penalty found that unemployed women increased their employment rate by 13 percentage points after starting GLP-1 treatment.
As EveryBODY Covered advocate Emily puts it: “When we effectively treat obesity, overall healthcare costs decrease with properly managed obesity. You will see a decrease in diabetes, complications, kidney disease, heart disease and more. Hospitalizations will decrease as these risks are better managed. Overall, insurance coverage of these medications and services should be a right, not a privilege, and by refusing to provide coverage for specialist visits and medications, direct harm is being done.”
leading the way: Bank of America bucks the trend and invests in obesity care
Bank of America is standing by its employees, covering GLP-1 medications and health coaching to support lasting lifestyle changes. CEO Brian Moynihan says the results speak for themselves. Pointing to the long-term health benefits and emerging evidence of nearer-term gains like fewer cardiovascular events, he notes, “We see a great impact on the employees.”
The bottom line: when employers cover comprehensive obesity care, the wins show up everywhere – healthier employees, stronger retention and bigger cost savings. Employers ready to lead can learn more here.